You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞信窩輪》港交所倒跌平安整固,留意港交購24692、平安購23509
阿思達克 11-16 13:04
大市成交回升,港交所(0388)周三曾走高逾1%,高見313.8元的逾兩個月高位水平,惟其後大市倒跌,股價亦跟隨跌逾2%,暫守300元關口。向上觀望上試320元水平的機會,短線觀望能否續守300元關口。看好可留意港交購24692,行使價347.38元,23年2月到期。或港交牛59729,收回價271.88元,行使價269.88元,23年9月到期。相反看淡可留意港交沽26434,行使價252.68元,23年4月到期。或港交熊68497,收回價324.00元,行使價326.00元,23年5月到期。 中國平安(2318)高見44.5元的近兩個月高位後反覆回落,曾下探43.5元水平。向上觀望收復45元水平的機會,40元關口或逐步重建支持。看好可留意平安購23509,行使價51.93元,23年2月到期。或平安牛59740,收回價36.88元,行使價36.28元,23年10月到期。相反看淡可留意平安沽26988,行使價30.72元,23年3月到期。或平安熊50502,收回價46.88元,行使價47.48元,23年4月到期。 匯豐(0005)曾挫逾2%,低位回落至44元以下。短線觀望上試100天線約46.4元的機會,10天線42.6元水平或可參考為支持。看好可留意匯豐購25481,行使價51.55元,23年3月到期。或匯豐牛58499,收回價40.88元,行使價39.88元,23年9月到期。相反看淡可留意匯豐沽26184,行使價33.95元,23年3月到期。或匯豐熊51097,收回價47.50元,行使價48.50元,23年4月到期。 友邦保險(1299)一度跌逾2%,低見74元,其後跌幅收窄。向上觀望挑戰250天線約77.2元的機會,70元關口或具不俗支持。看好可留意友邦購21676,行使價90.05元,23年6月到期。或友邦牛59734,收回價68.00元,行使價67.40元,23年7月到期。相反看淡則可留意友邦沽23965,行使價67.95元,23年12月到期。或友邦熊64181,收回價81.00元,行使價81.60元,23年5月到期。 藥明生物(2269)一度飆逾4%,高見56.3元的兩個月高位,但及後跟隨大市回軟。看好可留意藥明購11402,行使價60.05元,23年2月到期。或藥明牛59735,收回價43.88元,行使價42.38元,23年7月到期。相反看淡可留意藥明熊69637,收回價60.00元,行使價61.50元,23年4月到期。 以上產品資料來源: 彭博資訊及瑞信網站cswarrants.com (本結構性產品並無抵押品) 《瑞信香港認股證及牛熊證銷售主管何啟聰》 免責聲明:筆者為瑞士信貸(香港)有限公司的代表,為證監會持牌人,並無持有相關上市公司的任何財務權益。本文內容僅供參考,並不構成要約、建議或促使任何人士提呈買賣或認購任何證券。結構性產品價格可急升或急跌,投資者或會蒙受全盤損失。本產品並無抵押品。如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。牛熊證備強制贖回機制而可能被提早終止,屆時(i)N類牛熊證投資者將不獲發任何金額;而(ii)R類牛熊證之剩餘價值可能為零。有關恆生指數,恆生中國企業指數或恆生科技指數的免責聲明,請參閱上市文件。過往表現並不反映將來表現。投資前,投資者應瞭解風險,並諮詢專業顧問及查閱有關上市文件。瑞信之聯屬公司Credit Suisse Securities (Hong Kong) Limited為結構性產品之流通量提供者,亦可能是唯一報價者。本文任何內容概不構成投資、法律、會計或稅務意見、並無聲明任何投資或策略適合或符合閣下的個別情況。結構性產品交投量並不是結構性產品表現的指標,投資者不應僅依賴交投量歷史高位數據以釐定結構性產品日後的表現。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account